Comparison of drug resistance scores for tipranavir in protease inhibitor-naïve patients infected with HIV-1 B and non-B subtypes

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5362-5366

  Stürmer, Martin ^a   Stephan, Christoph ^a   Gute, Peter ^b   Knecht, Gaby ^b   Bickel, Markus ^a   Brodt, Hans Reinhard ^a   Doerr, Hans W ^a   Gürtler, Lutz ^a   Lecocq, Pierre ^c   Van Houtte, Margriet ^c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Infektiologikum   (Germany)

^c Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; TIPRANAVIR;

ALGORITHM; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PHENOTYPE; PRIORITY JOURNAL; SCORING SYSTEM;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MUTATION; PYRIDINES; PYRONES;

EID: 80054690362     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00611-11     Document Type: Article

References (30)

1. Abecasis, A. B., et al. 2006. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02-AG. Antivir. Ther. 11: 581-589. (Pubitemid 44277423)
2. Bannister, W. P., et al. 2006. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir. Ther. 11:707-715. (Pubitemid 44497166)
3. Baxter, J. D., et al. 2006. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J. Virol. 80:10794-10801. (Pubitemid 44628925)
4. Booth, C. L., et al. 2007. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J. Antimicrob. Chemother. 59:517-524. (Pubitemid 47073459)
5. Champenois, K., et al. 2008. Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms. AIDS 22: 1087-1089. (Pubitemid 351769750)
6. Colonno, R., et al. 2004. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J. Infect. Dis. 189:1802-1810. (Pubitemid 38657216)
7. Condra, J. H., et al. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276. (Pubitemid 26378401)
8. De Meyer, S., et al. 2006. Phenotypic and genotypic determinants of TMC114 (darunavir) resistance: POWER 1, 2 and 3 pooled analysis, poster 196. 8th Int. Congr. Drug Ther. HIV Infect., Glasgow, United Kingdom, 12 to 16 November 2006.
9. Hertogs, K., et al. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276. (Pubitemid 28114430)
10. Hicks, C. B., et al. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368:466-475. (Pubitemid 44142769)
11. Holguin, A., E. Ramirez de Arellano, P. Rivas, and V. Soriano. 2006. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev. 8:98-107. (Pubitemid 44043558)
12. Jacobsen, H., et al. 1995. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206:527-534.
13. Larrouy, L., et al. 2011. Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir. Antimicrob. Agents Chemother. 55:1754-1757.
14. Marcelin, A. G., et al. 2008. Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 52: 3237-3243.
15. Montes, B., et al. 2004. Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J. Acquir. Immune Defic. Syndr. 35:329-336. (Pubitemid 38332792)
16. Parkin, N., and C. Chappey. 2006. Protease mutations associated with higher or lower than expected tipranavir susceptibility based on the TPV mutation score, poster 637. 13th Conf. Retroviruses Opportunistic Infect., Denver, CO, 5 to 8 February 2006.
17. Partaledis, J. A., et al. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
18. Patick, A. K., et al. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42: 2637-2644. (Pubitemid 28462907)
19. Poveda, E., et al. 2008. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS 22:611-616. (Pubitemid 351674068)
20. Rusconi, S., et al. 2000. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob. Agents Chemother. 44: 1328-1332. (Pubitemid 30228313)
21. Sagir, A., et al. 2007. Trends of prevalence of primary HIV drug resistance in Germany. J. Antimicrob. Chemother. 60:843-848. (Pubitemid 47434265)
22. Scherer, J., et al. 2007. Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted score, poster P3.4/07. 11th Eur. AIDS Conf. (EACS), Madrid, Spain, 24 to 27 October 2007.
23. Scherer, J., et al. 2009. Improved tipranavir weighted score predicts virologic response in diverse treatment-experienced patient populations, poster 94. 7th Eur. HIV Drug Resist. Workshop, Stockholm, Sweden, 25 to 27 March 2009.
24. Sturmer, M., A. Berger, and H. W. Doerr. 2003. Modifications and substitutions of the RNA extraction module in the ViroSeq HIV-1 genotyping system version 2: effects on sensitivity and complexity of the assay. J. Med. Virol. 71:475-479. (Pubitemid 37309915)
25. Sturmer, M., A. Berger, and W. Preiser. 2004. HIV-1 genotyping: comparison of two commercially available assays. Expert Rev. Mol. Diagn. 4:281-291. (Pubitemid 38684705)
26. Sungkanuparph, S., et al. 2008. Tipranavir resistance associated mutations in protease inhibitor-naive patients with HIV-1 subtype A/E infection. J. Clin. Virol. 43:284-286.
27. Talbot, A., et al. 2010. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob. Agents Chemother. 54:2473-2479.
28. Turriziani, O., et al. 1994. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol. 38:297-298.
29. Wensing, A. M., et al. 2005. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis. 192:958-966. (Pubitemid 41266791)
30. Yerly, S., et al. 2007. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 21:2223-2229. (Pubitemid 350287221)